About PAION AG

Company Description

PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.

In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Year founded

2000

Served area

Worldwide

Headcount

51

Headquarters

Martinstraße 10-12, 52062 Aachen – Germany

Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume Average price
27.12.22 Siebert, Gregor Board Buy 24,110.26 € 27.12.22
22.12.22 Dieckow, StB Simone Close relation Buy 500,000.00 € 22.12.22
22.12.22 Fuchs, Anna-Louisa Close relation Other 0.00 € 22.12.22
22.12.22 Fuchs, Mary-Ann Close relation Other 0.00 € 22.12.22
21.12.22 Zeitfracht GmbH & Co. KGaA Close relation Buy 3,607,500.00 € 21.12.22
21.12.22 Schröter, Jasmin Close relation Sell 3,607,500.00 € 21.12.22

Shareholder information

Shares outstanding

71,336,992

IPO

Feb. 11, 2005

Designated Sponsor(s)

Oddo BHF Corporates & Markets AG

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.